Related Experiment Video
Updated: Aug 8, 2026
Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
Identification of Small Inhibitors for Human Metadherin, an Oncoprotein, through in silico Approach
Arif Ali Khattak1,2, Ayaz Ahmad2, Haider Ali Khattak3
1State Key Laboratory of Rice Biology and Ministry of Agriculture Key Laboratory of Molecular Biology of Crop Pathogens and Insects, Institute of Biotechnology, Zhejiang University, Hangzhou, 310058, People's Republic of China.
Aims:
Cancer is a disease that takes lives of thousands of people each year. There are more than 100 different types of cancers known to man. This fatal disease is one of the leading causes of death today.
Background:
Astrocyte elevated gene-1(AEG-1)/Metadherin (MTDH) activates multiple oncogenic signaling pathways and leads to different types of cancers. MTDH interacting with staphylococcal nuclease domain containing 1(SND1) supports the survival and growth of mammary epithelial cells under oncogenic conditions.
Objective:
Silencing MTDH or SND1 individually or disrupting their interaction compromises the tumorigenic potential of tumor-initiating cells. The aim of our present study was to investigate novel interactions of staphylococcal nuclease domain containing 1 (SND1) binding domain of AEG-1/MTDH with different lead compounds through molecular docking approach using MOE software.
Methods:
Molecular docking was done by docking the ChemBridge database against important residues of MTDH involved in interaction with SND1. After docking the whole ChemBridge database, the top 200 interactive compounds were selected based on docking scores. After applying Lipinski's rule, all the remaining chosen compounds were studied on the basis of binding affinity, binding energy, docking score and protein-ligand interactions. Finally, 10 compounds showing multiple interactions with different amino acid residues were selected as the top interacting compounds.
Results:
Three compounds were selected for simulation studies after testing these compounds using topkat toxicity and ADMET studies. The simulation study indicated that compound 32538601 is a lead compound for inhibiting MTDH-SND1 complex formation.
Conclusion:
These novels, potent inhibitors of MTDH-SND1 complex can ultimately help us in controlling cancer up to some extent.
Insights
Researchers identified a novel compound that inhibits the MTDH-SND1 complex, a key factor in cancer development. This discovery offers a potential new strategy for cancer treatment by targeting tumor-initiating cells.
Area of Science:
- Oncology
- Molecular Biology
- Computational Chemistry
Background:
- Astrocyte elevated gene-1 (AEG-1), also known as Metadherin (MTDH), is implicated in activating oncogenic pathways driving various cancers.
- MTDH interacts with staphylococcal nuclease domain containing 1 (SND1), promoting mammary epithelial cell survival and growth under oncogenic conditions.
Purpose of the Study:
- To investigate novel interactions between the SND1 binding domain of MTDH and potential lead compounds.
- To identify inhibitors of the MTDH-SND1 complex using a molecular docking approach.
Main Methods:
- Molecular docking of the ChemBridge database against MTDH residues involved in SND1 interaction.
- Selection of top compounds based on docking scores, Lipinski's rule, binding affinity, and energy.
- Identification of 10 compounds with multiple protein-ligand interactions.
Main Results:
- Three compounds underwent toxicity and ADMET studies.
- Compound 32538601 was identified as a lead compound for inhibiting MTDH-SND1 complex formation through simulation studies.
Conclusions:
- Novel inhibitors targeting the MTDH-SND1 complex show promise for cancer control.
- This research contributes to developing new therapeutic strategies against cancer by disrupting critical oncogenic interactions.
